D1 Capital Partners has led a $102m series D round for Inflammatix, whose existing shareholders include Stanford-StartX Fund.
Inflammatix, a US-based molecular diagnostics company based on research at Stanford University, closed a $102m series D round yesterday led by D1 Capital Partners.
OSF Healthcare Ventures, the investment arm of health system OSF Healthcare, also took part in the round, as did Northpond Ventures, Khosla Ventures and Think.Health.
Founded in 2016, Inflammatix is working on rapid diagnostic tests that detect a patient’s immune response to infections by analysing mRNA biomarkers using machine learning technology.
The tests are able to identify whether an infection is viral or bacterial, and determine the risk of it becoming severe. The cartridge-based point-of-care system, called Myrna, produces results within half an hour.
The money has been allocated to seeking regulatory clearance and international commercialisation of Myrna, as well as an acute infection and sepsis test called InSep. The cash will also drive the continued development of Inflammatix’s product pipeline.
…
Thierry Heles
Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
